import type { ITrialsRecords } from '@/@types/data';

const datum: ITrialsRecords[] = [
	{
		id: 'melanoma',
		title: 'Myeloma and Other Plasma Cell Dyscrasias',
		trials: [
			{
				id: 'hematology-oncology-myeloma-1',
				type: 'pdfCard',
				phase: 3,
				nct: 'NCT05730036',
				trialCardPdf: 'NCT05730036 (LINKER-MM3)_R20_LNVO-EM-0005_844REGN-MID',
				recruiting: true,
				labels: {
					title: '<strong>LINKER-MM3</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
					aside: 'Relapsed/refractory multiple myeloma',
				},
			},
			{
				id: 'hematology-oncology-myeloma-2',
				type: 'pdfCard',
				phase: 2,
				phaseMobile: '1/2',
				nct: 'NCT05828511',
				trialCardPdf: 'NCT058285111 (LINKER-MM4)_R21_Linvoseltamab-EM-0011_844REGN-MID',
				recruiting: true,
				labels: {
					title: '<strong>LINKER-MM4</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
					aside: 'Newly diagnosed multiple myeloma',
				},
			},
			{
				id: 'hematology-oncology-myeloma-3',
				type: 'external',
				phase: 2,
				phaseMobile: '1/2',
				nct: 'NCT03761108',
				externalLink: 'https://clinicaltrials.gov/study/NCT03761108',
				recruiting: true,
				labels: {
					title: '<strong>LINKER-MM1</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
					aside: 'Relapsed/refractory multiple myeloma',
				},
			},
			{
				id: 'hematology-oncology-myeloma-4',
				type: 'pdfCard',
				phase: 2,
				nct: 'NCT05955508',
				trialCardPdf: 'NCT05955508_Smoldering_MM_R18_844REGN-MID',
				recruiting: true,
				labels: {
					title: '<strong>LINKER-SMM1</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
					aside: 'High-risk smoldering multiple myeloma ',
				},
			},
			{
				id: 'hematology-oncology-myeloma-7',
				type: 'external',
				phase: 2,
				nct: 'NCT06140524',
				externalLink: 'https://clinicaltrials.gov/study/NCT06140524',
				recruiting: false,
				labels: {
					title: '<strong>LINKER-MGUS1</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
					aside: 'high-risk monoclonal gammopathy or non-high-risk smoldering multiple myeloma',
				},
			},
			{
				id: 'hematology-oncology-myeloma-5',
				type: 'pdfCard',
				phase: 1,
				nct: 'NCT05137054',
				trialCardPdf: 'NCT05137054 (LINKER-MM2)_LNVO-EM-0002',
				externalLink:
					'https://clinicaltrials.gov/study/NCT05137054?term=NCT05137054&rank=1',
				recruiting: true,
				labels: {
					title: '<strong>LINKER-MM2</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span> + Other Cancer Treatments',
					aside: 'Relapsed/refractory multiple myeloma',
				},
			},
			{
				id: 'hematology-oncology-myeloma-6',
				type: 'external',
				nct: 'NCT05673967',
				externalLink: 'https://clinicaltrials.gov/study/NCT05673967',
				nonInterventional: true,
				recruiting: false,
				labels: {
					title: '<strong>NCT05673967</strong> Non-interventional real-world experience',
					aside: 'Relapsed/refractory multiple myeloma',
				},
			},
		],
	},
	{
		id: 'lymphoma',
		title: 'Lymphoma',
		trials: [
			{
				id: 'hematology-oncology-lymphoma-1',
				type: 'pdfCard',
				phase: 3,
				nct: 'NCT06091254',
				trialCardPdf: 'OLYMPIA-1-R16_ODRO-EM-0002_844REGN-MID_Bleed',
				recruiting: true,
				labels: {
					title: '<strong>OLYMPIA-1</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span>',
					aside: 'Previously untreated follicular lymphoma',
				},
			},
			{
				id: 'hematology-oncology-lymphoma-2',
				type: 'pdfCard',
				phase: 3,
				nct: 'NCT06097364',
				trialCardPdf: 'OLYMPIA-2-R12_ODRO-EM-0004_844REGN-MID_Bleed',
				recruiting: true,
				labels: {
					title: '<strong>OLYMPIA-2</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> + Chemotherapy',
					aside: 'Untreated or relapsed/refractory follicular lymphoma',
				},
			},
			{
				id: 'hematology-oncology-lymphoma-3',
				type: 'pdfCard',
				phase: 3,
				nct: 'NCT06091865',
				trialCardPdf: 'OLYMPIA-3-R15_ODRO-EM-0003_844REGN-MID_3mmBleed',
				recruiting: true,
				labels: {
					title: '<strong>OLYMPIA-3</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> + Chemotherapy',
					aside: 'Untreated diffuse large B-cell lymphoma',
				},
			},
			{
				id: 'hematology-oncology-lymphoma-4',
				type: 'external',
				phase: 3,
				nct: 'NCT06230224',
				externalLink: 'https://clinicaltrials.gov/study/NCT06230224',
				recruiting: true,
				labels: {
					title: '<strong>OLYMPIA-4</strong> Odronextamab  <span class="ui-one-word">(CD20xCD3 bispecific)</span>',
					aside: 'Relapsed/refractory diffuse large B-cell non-Hodgkin Lymphoma',
				},
			},
			{
				id: 'hematology-oncology-lymphoma-5',
				type: 'external',
				phase: 3,
				nct: 'NCT06149286',
				externalLink: 'https://clinicaltrials.gov/study/NCT06149286',
				recruiting: true,
				labels: {
					title: '<strong>OLYMPIA-5</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> + Chemotherapy',
					aside: 'Relapsed/refractory follicular lymphoma and marginal zone lymphoma',
				},
			},
			{
				id: 'hematology-oncology-lymphoma-6',
				type: 'pdfCard',
				phase: 2,
				nct: 'NCT03888105',
				trialCardPdf: 'NCT03888105 (ELM 2)_R19_Odronextamab-EM-0009_844REGN-MID',
				recruiting: true,
				labels: {
					title: '<strong>ELM-2</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span>',
					aside: 'Relapsed/refractory B-cell non-Hodgkin lymphoma',
				},
			},
			{
				id: 'hematology-oncology-lymphoma-7',
				type: 'pdfCard',
				phase: 1,
				nct: 'NCT02290951',
				trialCardPdf: 'NCT02290951 (ELM 1)_R16_Odronextamab-EM-0008_844REGN-MID',
				recruiting: false,
				labels: {
					title: '<strong>ELM-1</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span>',
					aside: 'B-cell malignancies',
				},
			},
			{
				id: 'hematology-oncology-lymphoma-8',
				type: 'pdfCard',
				phase: 1,
				nct: 'NCT05685173',
				trialCardPdf: 'NCT05685173 (ATHENA 1)_R13_Odronextamab-EM-0010_844REGN-MID',
				recruiting: true,
				labels: {
					title: '<strong>ATHENA-1</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> + CD22xCD28 bispecific <span class="ui-one-word">(REGN5837)</span>',
					aside: 'Relapsed/refractory aggressive B-Cell Non-Hodgkin Lymphoma',
				},
			},
			{
				id: 'hematology-oncology-lymphoma-9',
				type: 'pdfCard',
				phase: 1,
				nct: 'NCT02651662',
				trialCardPdf: 'NCT02651662 CLIO 1_R12_Odronextamab-EM-0011_844REGN-MID',
				recruiting: false,
				labels: {
					title: '<strong>CLIO-1</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> + Cemiplimab <span class="ui-one-word">(PD-1 antibody)</span>',
					aside: 'Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma',
				},
			},
		],
	},
	{
		id: 'classical-hematology',
		title: 'Classical Hematology',
		trials: [
			{
				id: 'hematology-oncology-classical-hematology-1',
				type: 'pdfCard',
				phase: 3,
				nct: 'NCT05133531',
				trialCardPdf: 'NCT05133531 (ACCESS 1)_R15_POZ-CEM-EM-0010_844REGN-MID',
				recruiting: true,
				labels: {
					title: '<strong>ACCESS-1</strong> Pozelimab <span class="ui-one-word">(C5 monoclonal antibody)</span> + Cemidiran <span class="ui-one-word">(C5 RNAi)<sup>†</sup></span>',
					aside: 'Paroxysmal nocturnal hemoglobinuria',
				},
			},
			{
				id: 'hematology-oncology-classical-hematology-2',
				type: 'pdfCard',
				phase: 2,
				phaseMobile: '1/2',
				nct: 'NCT04409080',
				trialCardPdf: 'NCT04409080_R13_REGN7257-EM-0004_844REGN-MID_3mmBleed',
				recruiting: true,
				labels: {
					title: 'IL2RG blocking antibody <span class="ui-one-word">(REGN7257)</span>',
					aside: 'Severe aplastic anemia',
				},
			},
			{
				id: 'hematology-oncology-classical-hematology-3',
				type: 'external',
				phase: 2,
				nct: 'NCT05618808',
				externalLink: 'https://clinicaltrials.gov/study/NCT05618808',
				recruiting: true,
				labels: {
					title: 'Factor XI antibody <span class="ui-one-word">(REGN9933)</span>',
					aside: 'Thrombotic disorders',
				},
			},
			{
				id: 'hematology-oncology-classical-hematology-4',
				type: 'external',
				phase: 1,
				nct: 'NCT04601051',
				externalLink: 'https://clinicaltrials.gov/study/NCT04601051',
				recruiting: false,
				labels: {
					title: 'NTLA-2001 <span class="ui-one-word">(TTR gene editing)</span>††',
					aside: 'Transthyretin amyloidosis',
				},
			},
			{
				id: 'hematology-oncology-classical-hematology-5',
				type: 'external',
				nct: 'NCT05568459',
				externalLink: 'https://clinicaltrials.gov/study/NCT05568459',
				nonInterventional: true,
				recruiting: true,
				labels: {
					title: '<strong>HONEY-B</strong> Lead-in, non-interventional real-world study',
					aside: 'Hemophilia B',
				},
			},
		],
	},
];
export default datum;
